Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Aly Karsan is a leading figure in cancer genomics and precision oncology, with a primary focus on hereditary cancer syndromes and the development of clinically actionable genomic assays. His major contributions center on translating next-generation sequencing technologies into robust, validated diagnostic tools. Notably, he led the development of a clinically validated second-generation sequencing assay for detecting hereditary BRCA1 and BRCA2 mutations, a landmark study published in 2013 that has garnered 42 citations and set a standard for clinical-grade mutation detection in hereditary breast and ovarian cancer. This work directly impacts patient risk assessment and treatment decisions. Dr. Karsan has also advanced the field of sample tracking in genomic workflows, introducing unique sequence controls to ensure data integrity and reproducibility in high-throughput sequencing, as highlighted in his 2019 publication. His research bridges the gap between laboratory innovation and clinical application, making genomic testing more reliable and accessible. With a career dedicated to improving cancer diagnostics, Dr. Karsan’s work continues to influence how hereditary cancer risks are identified and managed in clinical practice.